Farxiga can be taken with or without food
Who should take Semaglutide GLP-1 Injections
SURMOUNT-2 ket efficacy results, source: reference [2] Additionally, 81.6% (10 mg) and 86.4% (15 mg) of people taking tirzepatide achieved at least 5% body weight reduction , the other co-primary endpoint, compared to 30.5% of those taking placebo
Overall, Semaglutide represents a promising new treatment option for obesity, which can help people achieve significant weight loss and improve their overall health
A wave of regulatory approvals particularly for cardiovascular disease signals broader therapeutic potential, and growing optimism extends to their use in areas such as neurodegenerative disorders and addiction medicine
However, they differ significantly: semaglutide acts through GLP-1, tirzepatide through GIP and GLP-1, and retatrutide through GLP-1, GIP, and glucagon